Elevated spermidine serum levels in mild cognitive impairment, a potential biomarker of progression to Alzheimer dementia, a pilot study

This cross-sectional study by Sternberg et al (2022) measured spermidine levels in frozen serum samples of 43 Alzheimers (AD) patients, 12 mild cognitive impairment (MCI) patients, and 21 age-matched controls. They report significantly higher Spermidine serum levels in MCI group compared to controls, suggesting a possible role of Spermidine in AD pathophysiology. However, the differences in Spermidine serum levels between AD and controls, and pure AD and controls did not reach statistical significance.